Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
2013-004054-21Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Lenalidomide plus R-CHOP with Placebo plus R-CHOP (2 arms). Primary endpoint: Progression-free survival. Started Jul 2014; status: active.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2013-004054-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004054-21.